HDAC9 and Duchenne muscular dystrophy: Further investigations are warranted to unravel the molecular mechanisms underlying the synergistic effects of HDAC inhibitors like VPA in this combined approach and to refine strategies that maximize clinical benefits for DMD patients and potentially other neuromuscular disorders.